HCIT Q2 Preview: Q2 Bars Still Low, Won‘t Take Much for Stocks to Move Higher

Research evidence excerpt

HCIT Q2 Preview: Q2 Bars Still Low, Won‘t Take Much for Stocks to Move Higher

USA | Healthcare Information Tech. EquityJulyResearch22, 2026

KEY STOCKS FEATURED INCLUDE:HCIT Q2 Preview: Q2 Bars Still Low, Won't Take

TICKER RATING PRICE TARGETMuch for Stocks to Move Higher

GDRX HOLD $3.00

The HCIT complex has fared better since Q1 earnings releases, with the group HIMS HOLD $31.00

outperforming broader tech/software (IGV) during that period. While there DOCS HOLD $20.00

remains an AI overhang on the space, this appears priced into stocks at current HQY BUY $120.00

levels, and we believe earnings bars are still low and beats/raises will be ODD HOLD $16.00

rewarded with outsized upward stock moves. Top Picks into Prints: HQY and

WAY

Sentiment Has Bottomed Across HCIT But Still Not Great; Investors Remain Worried About AI, KEY CHANGES INCLUDE:

But No Longer Top-Of-Mind. We have seen an inflection in HCIT shares since the Q1 earnings TICKER RATING PRICE TARGET

season as the group overall has fully reflected investors' AI-related fears, and the recent pullback in

GDRX HOLD $3.00 ($2.60)

some AI Tech high-flyers appears to have brought incremental fund flows into HCIT shares that has

allowed the group to gain modest momentum in recent weeks. That said, sentiment and investor HIMS HOLD $31.00 ($24.50)

interest in the group remain relatively low, causing expectations bars to stay depressed; for this DOCS HOLD $20.00 ($19.00)

reason, we believe earnings beats/raises in Q2 will be rewarded with notable gains. HQY BUY $120.00 ($108.00)

Top Picks: ODD HOLD $16.00 ($10.25)

WAY: After the surprise patient billing revenue headwind that mgmt disclosed in Q1, shares•

have been volatile and are still -10% off pre-Q1 levels.